TY - JOUR
T1 - High-Dose vs. Low-Dose Dexamethasone in Patients With COVID-19
T2 - A Cohort Study in Rural Central America
AU - Montalvan-Sanchez, Eleazar
AU - Chambergo-Michilot, Diego
AU - Rodriguez-Murillo, Aida A.
AU - Brooks, Alexandra E.
AU - Palacios-Argenal, Dairy
AU - Rivera-Pineda, Shery
AU - Ordonez-Montes, Jose
AU - Estevez-Ramirez, Rosa
AU - Riva-Moscoso, Adrian
AU - Norwood, Dalton A.
AU - Calderon-Rodriguez, Alex
AU - Pineda-SanMartin, Elizabeth
AU - Giron, Roberto
AU - Rivera-Corrales, Luis
AU - Carcamo-Murillo, Balduino
AU - Garner, Orlando
N1 - Publisher Copyright:
© 2023 Ainosco Press. All rights reserved.
PY - 2023/3
Y1 - 2023/3
N2 - To compare the clinical outcomes of a low dose dexamethasone strategy vs. a high-dose dexamethasone strategy in hypoxemic COVID-19 patients. A retrospective observational study comparing low-dose (8 mg) and high-dose dexamethasone (24 mg) of COVID-19 patients admitted from September 1, 2020 to October 31, 2020 in a hospital in Honduras. We included 81 patients with confirmed COVID-19 who required oxygen therapy. The mean age was similar between groups (57.49 vs. 56.95 years). There were more male patients in the group of 24 mg (p = 0.01). Besides, patients on the 24 mg dose had more prevalence of hypertension (p = 0.052). More patients in the 24 mg group had a higher rate of invasive mechanical ventilation (15.00% vs. 2.56%, p = 0.058). When evaluating the association between the high dose group and outcomes, we find no significant association with mortality, nosocomial infections, high flow mask, invasive mechanical ventilation, or the need for vasopressors. We find no significant differences in the Kaplan–Meier analysis regarding the survival (log-rank p-value = 0.315). We did not find significant differences between the use of 24 mg and 8 mg of dexamethasone in hypoxemic COVID-19 patients.
AB - To compare the clinical outcomes of a low dose dexamethasone strategy vs. a high-dose dexamethasone strategy in hypoxemic COVID-19 patients. A retrospective observational study comparing low-dose (8 mg) and high-dose dexamethasone (24 mg) of COVID-19 patients admitted from September 1, 2020 to October 31, 2020 in a hospital in Honduras. We included 81 patients with confirmed COVID-19 who required oxygen therapy. The mean age was similar between groups (57.49 vs. 56.95 years). There were more male patients in the group of 24 mg (p = 0.01). Besides, patients on the 24 mg dose had more prevalence of hypertension (p = 0.052). More patients in the 24 mg group had a higher rate of invasive mechanical ventilation (15.00% vs. 2.56%, p = 0.058). When evaluating the association between the high dose group and outcomes, we find no significant association with mortality, nosocomial infections, high flow mask, invasive mechanical ventilation, or the need for vasopressors. We find no significant differences in the Kaplan–Meier analysis regarding the survival (log-rank p-value = 0.315). We did not find significant differences between the use of 24 mg and 8 mg of dexamethasone in hypoxemic COVID-19 patients.
KW - COVID-19
KW - Latin America
KW - Latinos or Hispanic
KW - Western Honduras
KW - cohort
KW - corticosteroids
UR - http://www.scopus.com/inward/record.url?scp=85165607514&partnerID=8YFLogxK
U2 - 10.6705/j.jacme.202303_13(1).0005
DO - 10.6705/j.jacme.202303_13(1).0005
M3 - Artículo
AN - SCOPUS:85165607514
SN - 2211-5587
VL - 13
SP - 36
EP - 40
JO - Journal of Acute Medicine
JF - Journal of Acute Medicine
IS - 1
ER -